How Robots and AI Are Automating the IVF Lab and What It Means for You

Surging global demand for IVF treatment has laid bare the inherent limitations of manual ICSI, which heavily relies on the embryologist’s real-time proficiency, hand steadiness, and even their physical condition on the day of treatment.

However, a wave of AI innovations in IVF technology emerging between 2025 and 2026 is breaking through the inherent limitations of manual IVF.

BAIBYS: The World’s First Autonomous AI-Powered Sperm Selection System

In April 2026, Israeli MedTech company BAIBYS™ announced a milestone. The first confirmed pregnancy was achieved using a fully autonomous AI-based robotic system for sperm selection.

The procedure took place in December 2025, performed by male infertility specialist Dr. Nino Guy Cassuto in Paris, involving a 37-year-old patient. The pregnancy has now passed the first trimester.

Why does this matter? ICSI represents the most technically demanding and manually intensive core stage within the full IVF workflow.

Under WHO criteria, over 96% of sperm in a typical sample are considered morphologically abnormal. High-magnification sperm selection can reduce structural birth defects by an estimated 45%.

Also, manual high-magnification screening is time-consuming, subjective, and requires extraordinary skill, taking up to three hours per procedure. BAIBYS’s system uses advanced AI to automatically classify sperm according to WHO criteria for both motility and morphology.

In validation studies, the AI’s classification showed 95% agreement with human clinicians.

The system has received CE Mark certification (January 2025), ISO 13485:2016 certification, and a U.S. patent. It has also secured up to $4.3 million in funding from the Israel Innovation Authority.

Remote-Controlled ICSI: Fertilization from 3,700 Kilometers Away

In March 2025, Reproductive BioMedicine Online published a landmark case report.

A team from Conceivable Life Sciences (New York) and clinics in Mexico demonstrated the world’s first live birth achieved through a fully automated, digitally controlled, remotely operated ICSI system.

The patient was a 40-year-old woman treated at Hope IVF in Mexico, so the system was set up locally, with some operational commands issued by a remote operator located 3,700 kilometers away in New York.

Five eggs were allocated to the automated ICSI system, with three used as a manual control. As a result, the automated ICSI group achieved 80% (4/5) normal fertilization, compared to 100% (3/3) in the manual control group. Both groups produced two usable blastocysts each.

Ultimately, a blastocyst fertilized by the automated ICSI group was thawed and transferred,  resulting in a healthy live birth at 38 weeks of gestation.

The study concluded that this milestone highlights the potential for automated systems to transform assisted reproductive technology practices globally, enhancing accessibility and standardization.

Overture Life: Automated ICSI Goes Clinical Across Five Countries

In June 2026, Overture Life announced the launch of its global ICSI.A Center of Excellence Program that brings the world’s first automated ICSI workstation into clinical use. They will establish the first five leading fertility centers in five countries, including Peru, Turkey, Bolivia, South Korea, and Argentina.

The ICSI.A platform integrates robotics and computer vision to standardize each injection, reducing the variability and manual error inherent in the most delicate step of IVF.

The platform is designed to augment, not replace, the embryologist, eliminating the physical burden and inconsistency of manual injections so clinical teams can focus on higher-level judgment and patient care.

Overture Life has already achieved the world’s first live births from robot-assisted fertilization and robot-assisted egg freezing. The company has raised over $100 million in funding, including a recent €20 million loan from the European Investment Bank.

“This is a turning point for reproductive medicine. The most critical step in IVF is no longer left to chance, and that changes what every clinic in the world can promise to its patients.”CEO Hans Gangeskar told the press at the launch.

What This Means

A June 2026 review in the Journal of Assisted Reproduction and Genetics analyzed the current landscape of automated IVF lab technology.

The authors noted that automated ICSI has produced healthy live births in proof-of-concept clinical studies, but clinical translation remains in its very early stages. Supporting data varies widely across automation modules, and full-system advantages remain unproven.

Even so, the industry trajectory is clear: IVF labs are shifting from manual craftsmanship to consistent standardization. Assisted reproduction is ushering in a new era built on precision and uniform clinical outcomes.

How CEF Can Help

If you are considering IVF and are interested in how these technologies might apply to your treatment, CEF is here to help.

1. Understanding emerging technologies: Some overseas centers are beginning to offer automated ICSI and AI-assisted sperm selection. We can help you understand the principles and eligibility criteria for these new approaches.

2. Second opinions: Fertility treatment decisions often benefit from multiple perspectives. We can help organize your medical records and facilitate expert consultations.

3. Personalized planning: Based on your specific diagnosis and needs, we can help map out your next steps, whether or not they involve cross-border care.

>For more information, email info@cefivf.com or visit our Contact page.